StockTipsArenaBeta

BUY Alkem Laboratories Limited — Somil Mehta, Sharekhan

BUYAlkem Laboratories Limited

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))30 Jul 2026via CNBC Awaaz.

Entry₹5,689Inferred
Target₹6,150
Total upside +8.10% (call closed)
Stop loss₹5,680-0.16% risk
Exit₹5,6803 Aug 2026, 9:40 am
Stop-loss hit-0.16%
Follow Somil Mehta for new calls(25% target hit, 178 closed calls)Get alertsWatch ALKEM for new buy/sell callsGet alertsSee 262 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 3 Aug 2026
9 supporting2 neutral0 opposing
Supports the BUY call (9)

Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street

NewsLivemint·20 Jul · 2w ago

(opens in new tab)

Alkem Laboratories Share Price: મોટી આંતરરાષ્ટ્રીય ડીલ પૂર્ણ! સ્વિસ કંપની Occlutech Holding AG માં મેજર હિસ્સો હસ્તગત

NewsGoogle News·17 Jul · 2w ago

(opens in new tab)

Alkem Laboratories: స్విస్ కంపెనీ Occlutech Holding AG కొనుగోలు పూర్తి

NewsGoogle News·17 Jul · 2w ago

(opens in new tab)

Alkem Laboratories: சுவிஸ் நிறுவனத்தில் பங்குதாரர் ஆனார்! மருத்துவ சாதன உலகில் புதிய அத்தியாயம்

NewsGoogle News·17 Jul · 2w ago

(opens in new tab)

Alkem Laboratories completes acquisition of Occlutech Holding AG

NewsGoogle News·17 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Alkem Laboratories accepts resignation of Dr. Jitendra Singh Huda

NewsGoogle News·25 Jul · 1w ago

(opens in new tab)

Alkem Laboratories Ltd has acquired 79,36,50,794 equity shares at Rs. 13.86 per share from its wholly owned subsidiary, Alkem Medtech Private Limited, on a rights basis. The acquisition aims to secure

BSE · Company Update·16 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.